We aimed to minimize the potential biases inherent in a retrospective cohort analysis by having relatively strict inclusion criteria and focusing on patients receiving their first therapy for CML-MBP and excluding patients with EM-only disease. Here, MBP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.